ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2833

Negative Regulator, MiR-23a, Down-Regulated in Psoriatic Arthritis. Implications for Disease Pathogenesis

Sarah Wade1, Michelle Trenkmann1, Trudy McGarry1, Douglas J. Veale2 and Ursula Fearon1, 1St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, 2St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: MicroRNA and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Psoriatic Arthritis (PsA) is a chronic immune-mediated inflammatory disease, characterised by proliferation of synovial tissue and progressive destruction of articular cartilage/bone associated with psoriasis. These processes may be governed by microRNA (miRNA), a class of small non-coding RNAs which exert their function through suppression of specific target genes. Altered miR-23a expression has been previously associated with angiogenic and pro-inflammatory mechanisms in other diseases. To date, altered miRNA expression and regulation has not been examined in PsA.

Methods:  Synovial tissue biopsies were obtained under direct visualisation from site of inflammation by needle arthroscopy, along with peripheral blood mononuclear cells (PBMC) from PsA (n=8), osteoarthritis (OA) (n=7), and healthy controls (n=8). To examine possible factors involved in regulating miRNA expression, primary PsA synovial fibroblasts (SFC) were isolated and cultured with candidate pro-inflammatory stimuli including TLR ligands: Pam3CSK4 (1 µg/ml), LPS (1 µg/ml), polyIC (10 µg/ml) and pro-inflammatory cytokines: IL-1β (1 ng/ml), TNFα (10 ng/ml) and IL-17 (20ng/ml). Total RNA was extracted using the Qiagen miRNeasy kit, and expression of miR-23a was measured by Sybr Green real-time PCR.  In parallel, IL-6, IL-8 and MCP-1 were quantified in culture supernatants by ELISA. Clinical demographics such as CRP, TJC, SJC and patient global were also assessed. 

Results:  A significant increase in miR-23a expression was demonstrated in PsA PBMC versus OA (p=0.0476) and HC (p=0.0186). In contrast, a significant decrease in miR-23a expression was observed in PsA synovial tissue compared to OA (p=0.0172). In PsA, synovial miR-23a expression negatively correlated with matched PBMC miR-23a (r=-1.00, p=0.0167), demonstrating a dissociation in miR-23a expression between systemic and local inflammation. Furthermore, miR-23a expression in PsA synovial biopsies inversely correlated with DAS28-CRP (r= -0.5294, p=0.035). TLR activation via PolyIC (TLR3) and LPS (TLR4) significantly decreased miR-23a expression in primary PsA SFC (all p<0.05), with no effect observed for pro-inflammatory cytokines. This was paralleled by a significant induction of IL-6, IL-8 and MCP-1 in response to LPS and PolyIC (all p<0.05). Finally, in silico analysis identified putative targets for miR-23a including PDE4B and PTK2B, which are known to be involved in multiple immune pathways, osteoclast function and angiogenic mechanisms.

Conclusion:  This is the first report of altered expression and regulation of miRNA in PsA, levels of which were inversely associated with increased joint inflammation. MiR-23a may be an important regulator of pathogenesis in PsA and may represent a potential target for therapeutic strategies. Further work will examine the functional role of miR-23a and it’s implications on disease pathogenesis in PsA.


Disclosure: S. Wade, None; M. Trenkmann, None; T. McGarry, None; D. J. Veale, None; U. Fearon, None.

To cite this abstract in AMA style:

Wade S, Trenkmann M, McGarry T, Veale DJ, Fearon U. Negative Regulator, MiR-23a, Down-Regulated in Psoriatic Arthritis. Implications for Disease Pathogenesis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/negative-regulator-mir-23a-down-regulated-in-psoriatic-arthritis-implications-for-disease-pathogenesis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/negative-regulator-mir-23a-down-regulated-in-psoriatic-arthritis-implications-for-disease-pathogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology